Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...
Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell line developme...
IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small blood vessels. It is caused by ...
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, announced new preclin...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
Pfizer Inc. announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...
MDDAP is empowering professionals with new opportunities to excel in the medical device sector through a cutting-edge learning pathway designed for the Vol...
In this exclusive interview with BioPharma BoardRoom, Mike Kadan, PhD, MBA, Chief Operating Officer of Vector BioMed, shares how the company is reimagining...
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...
Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commer...
Global pharmaceutical giants have unveiled over $160 billion in fresh U.S. investments within just the past few...
Ascletis Pharma Inc. announces positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...
Regeneron Pharmaceuticals, Inc. announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotec...
Bristol Myers Squibb announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline...
© 2025 Biopharma Boardroom. All Rights Reserved.
